Fortrea Holdings 경영진
경영진 기준 점검 0/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Anshul Thakral
최고경영자
US$12.2m
총 보수
| CEO 급여 비율 | 3.30% |
| CEO 재임 기간 | less than a year |
| CEO 지분 보유율 | n/a |
| 경영진 평균 재임 기간 | less than a year |
| 이사회 평균 재임 기간 | 2.6yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jul 14
FTRE: Steady Utilization And Execution Risks Will Restrain Future Share Upside
Fortrea Holdings' analyst price target has moved higher, with recent updates pointing to a range of $16 to $18 as analysts factor in steadier healthcare utilization trends and more supportive sentiment toward life science tools in their forecasts. Analyst Commentary Recent research updates on Fortrea Holdings show price targets consolidating in the mid-teens, with most commentary linked to broader readthroughs from healthcare utilization surveys and sentiment toward life science tools rather than company specific catalysts.
내러티브 업데이트 • Jun 22
FTRE: Execution On 2026 Guidance And AI Rollout Will Shape Risk Reward
Fortrea Holdings' updated analyst price target has moved higher to $16.21 from $14.44. This reflects analysts' use of a lower discount rate, slightly stronger assumptions for revenue growth and profit margins, and a modestly higher future P/E multiple supported by a series of recent target increases across major firms.내러티브 업데이트 • Jun 08
FTRE: Ongoing Execution Risks Around 2026 Guidance Will Limit Upside Potential
Analysts have lifted their aggregate price target on Fortrea Holdings by several dollars to reflect updated assumptions for revenue growth, margins and future P/E expectations, following a series of recent target increases from major firms. Analyst Commentary Recent research on Fortrea reflects a mix of optimism and caution, with some firms lifting price targets and others trimming their expectations as they reassess the stock's risk and reward trade off.
내러티브 업데이트 • May 25
FTRE: Conservative 2026 Guidance And AI Tools May Drive Re Rating
Analysts raised Fortrea Holdings’ fair value estimate to $20.00 from $16.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E that are consistent with a series of recent price target increases across the Street. Analyst Commentary Recent Street research around Fortrea has shifted toward a more constructive tone, with several bullish analysts lifting price targets and one firm moving the stock to a higher rating category.내러티브 업데이트 • May 07
FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside
Analysts have raised their price targets on Fortrea by $3 to $5, and the fair value estimate in this model has shifted from $5.0 to $9.5 as analysts point to moderating discount rate assumptions, slightly positive revenue growth, and higher expected profit margins reflected in a higher forward P/E multiple. Analyst Commentary Recent research on Fortrea shows a split view, with some firms raising price targets by US$3 to US$5, while others have taken a more cautious stance, trimming targets and questioning how much upside is already reflected in the valuation.내러티브 업데이트 • Apr 21
FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating
The analyst price target for Fortrea has been reset from about $22.59 to $16.00 as analysts factor in updated fair value assumptions, slightly lower revenue growth and profit margin inputs, and a lower future P/E multiple, while also incorporating recent Street research that adjusts targets across firms in response to evolving views on the company's fundamentals and guidance. Analyst Commentary Recent Street research on Fortrea shows a mix of trimmed price targets and selective upgrades, as analysts recalibrate their models around updated guidance and sector views.내러티브 업데이트 • Apr 07
FTRE: Margin Recovery Under New Leadership And Conservative 2026 Guidance May Drive Re Rating
Analysts nudged their price target for Fortrea slightly higher to $22.59 from $22.46, citing a mix of higher assumed profit margins, a lower future P/E multiple, and varied recent Street calls that balance upgraded ratings with trimmed targets in the $12 to $22 range. Analyst Commentary Recent Street research on Fortrea shows a wide range of opinions, but the most optimistic voices point to improving execution, clearer profit potential, and room for the shares to rerate as fundamentals stabilize.내러티브 업데이트 • Mar 24
FTRE: Margin Recovery And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update The analyst price target for Fortrea has been revised lower from about $25 to roughly $22.46. This reflects analysts balancing recent price target cuts from several banks with more constructive views that cite improving execution, better fundamentals, and a clearer path to margin recovery under new leadership.내러티브 업데이트 • Mar 09
FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside
The analyst price target for Fortrea Holdings has shifted lower by about $2 to align with a refreshed fair value estimate of $14.44, as analysts factor in a higher discount rate, more cautious revenue growth assumptions, and only modestly revised margin and P/E inputs, despite recent rating upgrades and mixed target resets across the Street. Analyst Commentary Street research on Fortrea paints a mixed picture, with several firms turning more constructive on execution and earnings power, while others temper expectations for share price upside through lower targets.내러티브 업데이트 • Feb 23
FTRE: Execution Improvements And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update on Fortrea Holdings: Analyst Price Target Shift The updated analyst price target for Fortrea Holdings reflects a higher implied valuation in dollar terms. Analysts are citing improved execution under new leadership, a clearer path to margin recovery, and recent target increases from firms that now see better revenue trends, margin potential, and benefits from deleveraging.분석 기사 • Feb 12
The Market Doesn't Like What It Sees From Fortrea Holdings Inc.'s (NASDAQ:FTRE) Revenues Yet As Shares Tumble 33%
Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have retraced a considerable 33% in the last month, reversing a fair...내러티브 업데이트 • Feb 09
FTRE: Execution And Margin Recovery Under New Leadership Will Drive Future Upside
Narrative Update: Fortrea Holdings Our updated analyst price target for Fortrea moves higher by about $3, with analysts pointing to improving execution under new leadership, early commercial traction, a clearer path to margin recovery, and more supportive biopharma demand as key reasons for their revised expectations. Analyst Commentary Recent Street research on Fortrea reflects a more constructive tone, with several bullish analysts lifting price targets and upgrading ratings as they reassess the company’s execution, growth prospects, and margin potential.내러티브 업데이트 • Jan 25
FTRE: Execution Gains And Biopharma Cycle Tailwinds May Drive Re Rating
Narrative Update on Fortrea Holdings Analysts have lifted their blended price expectations for Fortrea by several dollars, with new targets in the low to mid $20s and up to $25, citing improving execution under new leadership, a clearer path to margin recovery, and better perceived performance as the biopharma cycle picks up. This is broadly consistent with only modest tweaks to our discount rate, revenue growth, margin and future P/E assumptions and no change to our $25.00 fair value estimate.내러티브 업데이트 • Jan 11
FTRE: New Leadership And Margin Recovery Path May Drive Re Rating
Analysts have raised their blended price target on Fortrea Holdings to about $25 from roughly $13, reflecting updated assumptions for stronger revenue growth, slightly improved profit margins, and a higher future P/E multiple, alongside recent upgrades and target increases from several firms. Analyst Commentary Bullish analysts are becoming more constructive on Fortrea Holdings, with a series of upgrades and price target increases that highlight improving company execution and a more supportive setup for profitability and valuation.내러티브 업데이트 • Dec 27
FTRE: Rapid Share Gains Will Be Tested By Leadership Execution Risks
Analysts have nudged their average price target on Fortrea Holdings higher, from $12.07 to $13.25, citing encouraging early progress under new leadership, a steady Q3 book-to-bill backdrop, and signs that contract research and healthcare utilization trends may be stabilizing into 2026. Analyst Commentary Recent research updates reflect a cautiously constructive stance on Fortrea, with incremental target price hikes tied to operational progress and a stabilizing industry backdrop.내러티브 업데이트 • Dec 13
FTRE: Rapid Share Gains Will Face Test From Leadership Transition Execution
Analysts have raised their fair value estimate for Fortrea Holdings from $11.21 to $12.07 per share, citing a lower perceived discount rate, slightly stronger long term revenue growth assumptions, and improving demand signals reflected in multiple recent price target increases across the Street. Analyst Commentary Bullish analysts point to a constructive setup for Fortrea as recent price target increases cluster in a narrow range above the prior consensus, suggesting growing confidence that execution under new leadership can support a re-rating.분석 기사 • Dec 07
Fortrea Holdings Inc. (NASDAQ:FTRE) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have been powering on, with a gain of 27...내러티브 업데이트 • Nov 29
FTRE: Rapid Share Price Increase Will Challenge Upside Amid Mixed Industry Trends
Analysts have raised their average price target for Fortrea Holdings. Recent targets have moved from approximately $7-11 previously to as high as $14, reflecting improving internal execution, stabilizing industry trends, and cautious optimism regarding future demand.Seeking Alpha • Nov 20
Fortrea Holdings: Showing Real Signs Of Life
Summary Fortrea Holdings has shown signs of recovery after severe operational and financial struggles, with shares rebounding from historic lows. The company reported improving sales momentum and a rising backlog, but EBITDA and margins remain under pressure, keeping leverage high. Management has implemented cost reductions, raised guidance, and enacted a shareholder rights plan, signaling renewed urgency and insider confidence. While the darkest scenarios seem less likely, conviction to buy remains low; continued monitoring is warranted as recovery progresses. Read the full article on Seeking Alpha내러티브 업데이트 • Nov 15
FTRE: Bookings Stability And Leadership Transition Will Shape Outlook Into 2026
Fortrea Holdings' analyst price target has increased significantly from $9.53 to $11.21, as analysts cite a more promising outlook supported by steady bookings, sector stabilization, and improving market demand. Analyst Commentary Recent analyst research highlights both positive developments and ongoing uncertainties for Fortrea Holdings.내러티브 업데이트 • Nov 01
FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
The analyst price target for Fortrea Holdings has been raised from $7 to a range between $9 and $10. Analysts cite stabilizing healthcare cost trends and improving contract research bookings as key factors for their more optimistic outlook.내러티브 업데이트 • Oct 18
Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their price target for Fortrea Holdings from $8.30 to $9.44, citing sustained improvements in revenue growth, stabilizing cost trends, and recent industry signals that point to a bottoming in contract research organization demand. Analyst Commentary Recent analyst updates highlight a shifting outlook for Fortrea Holdings, with both optimistic and cautious perspectives emerging from the latest research notes.내러티브 업데이트 • Oct 03
Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their fair value estimate for Fortrea Holdings from $7.89 to $8.30 per share. They cite recent improvements in industry bookings and biotech funding, despite continued mixed demand signals.내러티브 업데이트 • Sep 05
Global Demographic Trends Will Spur Clinical Advances
The upward revision in Fortrea Holdings’ price target is primarily driven by a lower discount rate, signaling reduced perceived risk and supporting the increase in fair value from $7.44 to $7.89. What's in the News Fortrea Holdings raised its full-year 2025 revenue guidance to $2.6–$2.7 billion.분석 기사 • Aug 14
Health Check: How Prudently Does Fortrea Holdings (NASDAQ:FTRE) Use Debt?
NasdaqGS:FTRE 1 Year Share Price vs Fair Value Explore Fortrea Holdings's Fair Values from the Community and select...내러티브 업데이트 • Aug 07
Global Demographic Trends Will Spur Clinical Advances
Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.분석 기사 • Jun 21
Why Fortrea Holdings Inc. (NASDAQ:FTRE) Could Be Worth Watching
Fortrea Holdings Inc. ( NASDAQ:FTRE ), is not the largest company out there, but it led the NASDAQGS gainers with a...새로운 내러티브 • May 17
New Therapeutic Areas And AI Adoption Will Fuel Progress
Expanding into therapeutic areas and strengthening partnerships may increase revenue through diversified client engagement.분석 기사 • May 08
Is There An Opportunity With Fortrea Holdings Inc.'s (NASDAQ:FTRE) 49% Undervaluation?
Key Insights Fortrea Holdings' estimated fair value is US$11.03 based on 2 Stage Free Cash Flow to Equity Fortrea...분석 기사 • Apr 08
Is Fortrea Holdings (NASDAQ:FTRE) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Mar 06
Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds
Summary FTRE's strong backlog of $7.7 billion provides revenue stability and planning advantages, despite short-term spin-off costs and missed earnings. The CRO market is projected to grow significantly, driven by increased outsourcing of complex late-stage trials, positioning FTRE for long-term growth. FTRE's global reach across 90 countries offers a competitive advantage in multi-region trials, enhancing patient enrollment and administrative efficiency. Post-spin-off, FTRE can focus on high-margin areas like oncology and decentralized trials, with expected margin improvements from reduced overhead costs. Read the full article on Seeking Alpha분석 기사 • Mar 04
Benign Growth For Fortrea Holdings Inc. (NASDAQ:FTRE) Underpins Stock's 38% Plummet
To the annoyance of some shareholders, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares are down a considerable 38% in the...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$447m |
| Dec 31 2025 | US$12m | US$402k | -US$986m |
보상 대 시장: Anshul의 총 보수(USD12.17M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.16M)보다 높습니다.
보상과 수익: Anshul의 보상을 회사 실적과 비교하기에 데이터가 부족합니다.
CEO
Anshul Thakral (48 yo)
less than a year
재임 기간
US$12,166,066
보수
Mr. Anshul Thakral is CEO & Director of Fortrea Holdings Inc. from August 4, 2025. Mr. Thakral is Senior Vice President of Pharmaceutical Product Development, LLC. He joined the Pharmaceutical Product Deve...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | less than a year | US$12.17m | 데이터 없음 | |
| COO & President of Clinical Services | 3.2yrs | US$1.62m | 0.080% $ 1.3m | |
| Executive Officer | no data | US$1.68m | 0.083% $ 1.4m | |
| President & Chief Commercial Officer | no data | 데이터 없음 | 데이터 없음 | |
| Chief Financial Officer | no data | 데이터 없음 | 0.00029% $ 4.9k | |
| Chief Accounting Officer | 1.9yrs | 데이터 없음 | 0.022% $ 362.1k | |
| Chief Information Officer | no data | 데이터 없음 | 데이터 없음 | |
| Chief Administrative Officer | 3.2yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP of Investor Relations | less than a year | 데이터 없음 | 데이터 없음 | |
| General Counsel & Corporate Secretary | less than a year | 데이터 없음 | 데이터 없음 | |
| Head of Corporate Development | no data | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | no data | 데이터 없음 | 데이터 없음 |
0.9yrs
평균 재임 기간
52yo
평균 나이
경험이 풍부한 관리: FTRE의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 0.9 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | less than a year | US$12.17m | 데이터 없음 | |
| Chairman of the Board & Lead Independent Director | 3.1yrs | US$2.45m | 0.26% $ 4.4m | |
| Independent Director | 1.3yrs | US$502.50k | 0.077% $ 1.3m | |
| Independent Director | less than a year | US$22.50k | 데이터 없음 | |
| Independent Director | 3.1yrs | US$300.00k | 0.055% $ 931.6k | |
| Independent Director | 3.1yrs | US$317.47k | 0.032% $ 534.9k | |
| Independent Director | 2.2yrs | US$310.00k | 0.049% $ 818.7k | |
| Independent Director | 3.1yrs | US$340.00k | 0.055% $ 931.6k |
2.6yrs
평균 재임 기간
59yo
평균 나이
경험이 풍부한 이사회: FTRE의 이사회는 경험이 부족한 것으로 간주됩니다(평균 재임 2.6 년) — 신규 이사회일 가능성이 있습니다.
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/19 07:24 |
| 종가 | 2026/07/17 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Fortrea Holdings Inc.는 13명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |